H.C. Wainwright reiterates Syndax stock Buy rating at $38 target

H.C. Wainwright has reaffirmed its Buy rating for Syndax Pharmaceuticals (NASDAQ:SNDX) stock with a $38.00 price target, indicating potential significant upside from the current trading price of $18.80. This rating reflects the company's consensus as a Strong Buy among Wall Street analysts specializing in biotech firms. Prior to the release of Syndax's third-quarter earnings, H.C.

Wainwright conducted thorough research focusing on NPM1m AML biology and market dynamics. Their investigation considered commercial assumptions for the NPM1m AML market in comparison to KMT2Ar, involving discussions with hematologist-oncologists to understand the integration of targeted therapies like Revuforj into various treatment algorithms.

The analysis revealed notable challenges stemming from frequent actionable co-mutations within the NPM1m market, which hinder the effectiveness of established targeted therapies during the treatment sequencing process. H.C. Wainwright emphasized that these obstacles originate from existing therapies, rather than menin inhibitors.

The firm retained its optimistic stance on Syndax Pharmaceuticals shares, affirming the $38 price target. Based on InvestingPro's valuation assessment, the stock appears to be undervalued compared to its intrinsic Fair Value. For readers interested in a more in-depth examination, a Pro Research Report is available, providing expert analysis and actionable intelligence on SNDX, alongside other top US equities.

In recent quarterly results, Syndax reported a revenue increase of 92% year-over-year, attributed to robust demand for its products, Revuforj and Niktimvo, generating $54.7 million and $18.1 million respectively. However, some analysts have lowered their price targets, such as BofA Securities and UBS, citing mixed reactions to the company's performance and upcoming Phase 2 data for axatilimab in idiopathic pulmonary fibrosis.